Key clinical point: Lansoprazole and famotidine appear to be comparable in preventing idiopathic ulcer recurrent bleeding.
Major finding: Ulcer confirmation via endoscopy detected one ulcer in the lansoprazole group and three in the famotidine group (0.9 vs. 2.6%, respectively; P = .62).
Study details: A single-center, double-blinded, randomized trial of 228 patients.
Disclosures: The trial was funded in part by the General Research Fund–Research Grant Council. Dr. Lau reported having no financial disclosures. Many of his coauthors reported having numerous financial ties to the pharmaceutical industry.
Lau L et al. DDW 2019, Abstract 322.